ArticleScientific reports2026
Quercetin and nanoquercetin mitigate high fat diet-induced obesity via lipid modulation, genomic DNA integrity restoration, adipokine regulation, and hepato-pancreatic tissue preservation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on active ingredients of traditional Chinese medicine in the treatment of asthenozoospermia.Frontiers in reproductive health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a global health challenge characterized by excessive fat accumulation and associated with life-threatening comorbidities such as type 2 diabetes, cardiovascular diseases, and certain cancers. Conventional treatments, including lifestyle modification and pharmacotherapy, often have limited long-term efficacy and potential side effects, highlighting the need for safer alternatives. Natural bioactive compounds, such as quercetin, a dietary flavonoid with antioxidant, anti-inflammatory, and metabolic regulatory properties, have emerged as promising anti-obesity agents. However, poor bioavailability limits its therapeutic application, prompting the development of nanoformulations. This study therefore estimated the anti-obesity potential of quercetin and nanoquercetin in a high-fat diet (HFD)-induced obesity model in male Wistar rats. Following acute toxicity testing, 36 rats were divided into six groups: non-obese control, obese HFD control, and non-obese or obese rats orally received quercetin or nanoquercetin at 10% of the safe dose daily for four weeks. Outcomes assessed included body weight, lipid profile, serum total protein, genomic DNA integrity, Adiponectin and Leptin gene expression, and histological changes in liver and pancreatic tissues. In non-obese rats, quercetin and nanoquercetin did not affect body weight and genomic DNA integrity but improved lipid profiles. Nanoquercetin additionally increased total protein levels. Both compounds upregulated Adiponectin expression in the liver, with nanoquercetin also enhancing pancreatic Adiponectin expression. Histology revealed preserved tissue architecture. In obese rats, administration of quercetin or nanoquercetin significantly reduced body weight, improved lipid and protein parameters, restored genomic DNA integrity, upregulated Adiponectin, downregulated Leptin, and markedly improved hepatic and pancreatic histological architecture. Nanoquercetin consistently produced more pronounced effects than quercetin.nIn. These findings demonstrate the therapeutic potential of quercetin, particularly its nanoform, as a multi-targeted anti-obesity agent. Its effects on metabolic regulation, genomic protection, and tissue preservation support further preclinical and clinical studies to explore its role as a safe and effective strategy for managing obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.